HaemaLogiX has strategic research partnerships with leading global cancer institutes, hospitals and cell therapy companies to progress the clinical development of its immunotherapies in multiple myeloma and related diseases.
In 2023, HaemaLogiX entered into a strategic partnership with Peter Mac to initiate a Phase 1 clinical trial of a KMA-targeted CAR-T cell therapy in patients with relapsed or refractory kappa-type multiple myeloma. This collaboration provides the Company with access to world-class clinical and manufacturing expertise and advanced cell therapy infrastructure located at Peter Mac. The Phase 1 trial is expected to generate early human proof-of-concept for HaemaLogiX’s highly targeted immunotherapy approach.
Building on this agreement, in March 2025, HaemaLogiX entered into a pre-clinical research agreement with Immuneel Therapeutics Private Limited (Immuneel), a leading immuno-oncology company, to evaluate the potential of KMA in CAR-T applications. This agreement is anticipated to enable the Company to leverage Immuneel’s capabilities in cell therapy innovation and manufacturing.
HaemaLogiX has a contract manufacturing agreement with Lonza Group AG (Lonza), a global leader in biologics manufacturing, to support the ongoing development and production of KappaMab™. Lonza is one of the world’s leading Contract Development and Manufacturing Organisations, specialising in monoclonal antibody production, with GMP-certified facilities that meet the strict requirements of regulatory agencies like the FDA, EMA, and TGA and will enable scalable clinical and commercial programs.
Under a collaboration agreement, Peter Mac conducts the KOALA Phase 1 trial of a KMA-directed CAR-T therapy in relapsed/refractory kappa-restricted myeloma, sponsored by its Centre of Excellence in Cellular Immunotherapy and funded through government and foundation grants. HaemaLogiX is the originator, owner and co-developer; the KMCAR™ therapy and underlying KMA and KappaMab™ technology are HaemaLogiX intellectual property.
HaemaLogiX has a long-standing research collaboration with Alfred Health, led by Professor Andrew Spencer. Through the Australasian Myeloma Research Consortium (AMaRC), Alfred Health conducted the AMaRC 01-16 study of KappaMab™ in relapsed/refractory kappa-restricted myeloma (British Journal of Haematology, 2023). HaemaLogiX also has a Collaboration and IP Assignment Agreement with Western Sydney Local Health District covering its CAR-T programs.
In March 2025, HaemaLogiX entered a pre-clinical research agreement with Immuneel Therapeutics, an India-based immuno-oncology company focused on affordable CAR-T access. The collaboration explores HaemaLogiX's KMA-directed technology with Immuneel's manufacturing capabilities, aiming to develop high-quality, scalable and affordable CAR-T therapies.
Yes. HaemaLogiX is open to strategic partnership, licensing and acquisition discussions with global pharmaceutical and biotechnology companies — a core element of its commercialisation strategy stated in its Prospectus. Engagement is timed around key clinical inflection points for the KappaMab™ Phase IIb and KMCAR™ Phase 1 programs. Enquiries: Dr Chris Baldwin, chris@haemalogix.com.
HaemaLogiX is a clinical-stage company progressing two trials in relapsed/refractory myeloma. Its stated strategy is to engage pharmaceutical partners at key clinical inflection points — including the KappaMab™ Phase IIb combination readout and the KMCAR™ Phase 1 first-in-human data — to support late-stage development, regional commercialisation and platform expansion. No specific partnering transactions have been announced.
KappaMab™ is HaemaLogiX's wholly-owned lead clinical asset. The intellectual property is vested in HaemaLogiX, which holds US FDA Orphan Drug Designation in multiple myeloma, and the product is manufactured by Lonza. Commercial structures for partnering — by territory, indication or development stage — are open for confidential discussion.
HaemaLogiX owns the KMCAR™ intellectual property, developed with Peter MacCallum Cancer Centre under an agreement in which all commercial rights vest in HaemaLogiX. The broader platform — LambdaMab™, LMCAR™ and a discovery-stage bispecific/trispecific pipeline — is wholly held by HaemaLogiX and covered by 84 patent filings across 10 families. Platform- and program-level structures are open for discussion.
Yes. HaemaLogiX welcomes discussions with qualified academic and clinical investigators on investigator-initiated research involving its KMA- and LMA-directed technology. Proposals can be directed to Dr Rosanne Dunn, Chief Scientific Officer, at rosanne@haemalogix.com.